NRX Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-12-31 was -3.31M shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 2.33M shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 49.60K shares, a 90.39% decline from fiscal 2021.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 516.02K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2022-12-31 | 49.60K shares 10-K · filed 2023-03-31 | |
| 2021-12-31 | -3.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 516.02K shares 10-K · filed 2023-03-31 |
| 2021-09-30 | 2.33M shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |